PCL102H1 Lecture Notes - Lecture 28: Warfarin, Epidermal Growth Factor Receptor, Socialized Medicine
Document Summary
Drug reimbursement-economic studies/budget impact = value of drug. Canadian agency for drugs and technologies in health: formulary - list of approved drugs and which ones are covered by, terminology benefits/plans. Patient and family: costs data sources, identify and quantify resources, unit costs, outcomes survive, immediate outcomes, quality of life. Quality-adjusted life year (qaly) integrates mortality and morbidity. Qaly = quality of health state * utility score during that state. 1 year with a disease = fraction of a healthy year: cost-effective analysis/cost-utility analysis. Benefits of alternate programs must be equivalent. Cost-effective analysis (cea: benefits not explicitly valued, difficult to compare across a wide range of programs. Cost-utility analysis (cua: benefits valued qalys. Ex: a new warfarin costs /year (up from pennies), but does not need daily monitoring = tradeoff. Incremental cost effective ratios (icers) = (cost of a cost of. B)/(outcome a outcome b: ,000/qaly = spending ,000 for 1 qaly, different grades of recommendation.
